-
Product Insights
NewCommunity Acquired Pneumonia – Drugs In Development, 2024
Empower your strategies with our Community Acquired Pneumonia – Drugs In Development, 2024 report and make more profitable business decisions. Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache, and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis, and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle. The Community Acquired Pneumonia drugs in development market research...
-
Product Insights
NewBronchiectasis – Drugs In Development, 2024
Empower your strategies with our Bronchiectasis – Drugs In Development, 2024 report and make more profitable business decisions. Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. This damage allows bacteria and mucus to build up in the lungs. Bronchiectasis is divided into two categories: cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss, and fever. Causes of bronchiectasis include inhaling a foreign object, cystic...
-
Product Insights
NewBronchitis – Drugs In Development, 2024
Empower your strategies with our Bronchitis – Drugs In Development, 2024 report and make more profitable business decisions. Bronchitis is an inflammation of the lining of bronchial tubes, which carry air to and from lungs. Symptoms include cough that produces mucus (sputum), which may be blood streaked; shortness of breath aggravated by exertion or mild activity; frequent respiratory infections worsen symptoms; wheezing, fatigue, and headaches. Risk factors include smoking, older age and gastric reflux. The Bronchitis drugs in development market research...
-
Product Insights
NewAllergic Rhinitis – Drugs In Development, 2024
Empower your strategies with our Allergic Rhinitis – Drugs In Development, 2024 report and make more profitable business decisions. Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy or runny nose, sneezing, swollen...
-
Product Insights
NewAllergic Asthma – Drugs In Development, 2024
Empower your strategies with our Allergic Asthma – Drugs In Development, 2024 report and make more profitable business decisions. Allergic asthma is a type of asthma triggered by exposure to allergens, substances that induce an allergic reaction in susceptible individuals. When someone with allergic asthma encounters these triggers, their immune system responds by inflaming and constricting the airways, leading to symptoms of asthma. Common allergens that can trigger asthma include pollen, dust mites, pet dander, mold, cockroach droppings, and certain foods....
-
Product Insights
NewHospital Acquired Pneumonia (HAP) – Drugs In Development, 2024
Empower your strategies with our Hospital Acquired Pneumonia (HAP) – Drugs In Development, 2024 report and make more profitable business decisions. Hospital-acquired pneumonia (HAP) is defined as pneumonia acquired during a hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache, and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis, and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle. The Hospital Acquired Pneumonia (HAP) drugs in development market research report...
-
Product Insights
NewInterstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2024
Empower your strategies with our Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Interstitial lung disease (ILD) is a term that covers a variety of disorders that cause scarring or inflammation of the lung tissue. The scarring or inflammation affects the ability of the lungs to transfer oxygen to the blood. ILD can be caused by many factors, such as exposure to environmental toxins, certain medications, autoimmune diseases, infections, or...
-
Product Insights
NewVentilator Associated Pneumonia (VAP) – Drugs In Development, 2024
Empower your strategies with our Ventilator Associated Pneumonia (VAP) – Drugs In Development, 2024 report and make more profitable business decisions. Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in...
-
Product Insights
NewAcute Lung Injury – Drugs In Development, 2024
Empower your strategies with our Acute Lung Injury – Drugs In Development, 2024 report and make more profitable business decisions. Acute lung injury (ALI) is a severe and potentially life-threatening condition characterized by sudden and significant damage to the lungs, resulting in impaired gas exchange and respiratory function. ALI is now often grouped under the broader term acute respiratory distress syndrome (ARDS). ALI can result from various direct causes, including pneumonia, aspiration of gastric contents, near-drowning, inhalation of toxins or smoke,...
-
Product Insights
NewRespiratory Distress Syndrome – Drugs In Development, 2024
Empower your strategies with our Respiratory Distress Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Respiratory distress syndrome (RDS) occurs in babies born early (premature) whose lungs are not fully developed. The earlier the infant is born, the more likely it is for them to have RDS and need extra oxygen and help breathing. It primarily affects premature infants due to insufficient surfactant, a lung-stabilizing substance. Without surfactant, the lungs collapse, causing breathing difficulties. Common in...